Valuation: Galderma Group AG

Capitalization 48.46B 41.56B 38.86B 36.3B 67.58B 4,353B 73.21B 456B 176B 2,057B 182B 178B 7,500B P/E ratio 2025 *
97.9x
P/E ratio 2026 * 56x
Enterprise value 50.47B 43.28B 40.48B 37.8B 70.39B 4,534B 76.25B 475B 183B 2,142B 189B 185B 7,811B EV / Sales 2025 *
9.55x
EV / Sales 2026 * 7.99x
Free-Float
35.38%
Yield 2025 *
0.15%
Yield 2026 * 0.28%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.31%
1 week+2.63%
Current month+2.31%
1 month+6.78%
3 months+15.53%
6 months+45.51%
Current year+62.66%
More quotes
1 week 156.3
Extreme 156.3
164.8
1 month 143
Extreme 143
164.8
Current year 72.7
Extreme 72.7
164.8
1 year 72.7
Extreme 72.7
164.8
3 years 60
Extreme 60
164.8
5 years 60
Extreme 60
164.8
10 years 60
Extreme 60
164.8
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
+0.31%+2.63%+83.03% - 48.41B
-0.12%-1.02%+10.67%+2.23% 230B
-0.21%-1.66%-6.63%+12.42% 18.15B
+1.64%+4.86%-14.30%-62.90% 5.55B
-0.96%-0.88%+13.97%-5.70% 5.34B
+1.56%+8.49%-40.16%+47.70% 4.79B
-0.57%+0.06%+159.61% - 4.29B
-1.65%-1.85%-24.80%-44.31% 3.91B
-1.45%+2.73%-55.80%-57.99% 3.01B
+0.11%+1.50%-41.12%-17.33% 2.63B
Average -0.12%+1.20%+8.45%-15.74% 32.57B
Weighted average by Cap. -0.05%-0.26%+19.84%+0.71%
See all sector performances

Financials

2025 *2026 *
Net sales 5.2B 4.46B 4.17B 3.89B 7.25B 467B 7.85B 48.9B 18.87B 221B 19.51B 19.09B 804B 6.17B 5.29B 4.95B 4.62B 8.6B 554B 9.32B 58.05B 22.4B 262B 23.16B 22.66B 955B
Net income 544M 466M 436M 407M 758M 48.85B 822M 5.12B 1.97B 23.08B 2.04B 2B 84.17B 901M 773M 723M 675M 1.26B 80.97B 1.36B 8.48B 3.27B 38.26B 3.38B 3.31B 139B
Net Debt 2.01B 1.73B 1.61B 1.51B 2.81B 181B 3.04B 18.94B 7.31B 85.43B 7.55B 7.39B 312B 1.25B 1.07B 1B 937M 1.74B 112B 1.89B 11.76B 4.54B 53.07B 4.69B 4.59B 194B
More financial data * Estimated data
Logo Galderma Group AG
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Employees
-
More about the company
Date Price Change Volume
04/12/25 163.70 CHF +0.31% 269,021
03/12/25 163.20 CHF +3.23% 306,917
02/12/25 158.10 CHF 0.00% 268,603
01/12/25 158.10 CHF -1.19% 322,280
28/11/25 160.00 CHF +0.31% 248,820

Delayed Quote Swiss Exchange, December 04, 2025 at 04:30 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
204.13USD
Average target price
195.52USD
Spread / Average Target
-4.22%
Consensus

Quarterly revenue - Rate of surprise